4.7 Article

Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs

Journal

DIABETES OBESITY & METABOLISM
Volume 14, Issue 5, Pages 424-432

Publisher

WILEY
DOI: 10.1111/j.1463-1326.2011.01552.x

Keywords

antidiabetic drugs; obesity; secular trends; type 2 diabetes; weight change

Funding

  1. BMS
  2. Astra Zeneca of the United Kingdom Retrospective Diabetes Study (UKRDS)
  3. Astellas
  4. Diabetes UK
  5. Engineering and Physical Sciences Research Council
  6. European Association for the Study of Diabetes
  7. Ferring
  8. GSK
  9. Lilly
  10. Medical Research Council
  11. Medtronic
  12. Merck
  13. National Health Service
  14. Pfizer
  15. Sanofi-Aventis
  16. Wyeth

Ask authors/readers for more resources

Aim: This study aimed to describe the pattern of weight change in people with type 2 diabetes (T2DM) over time and when using alternative treatment regimens. Methods: Data were from routine clinical practice in the UK. The weight trend was determined for each year from 1995 to 2010 for both prevalent and incident cases. Baseline weight was compared to absolute (mean Delta) and relative weights (% Delta) at 6, 12 and 24 months. Results: Mean, standardized weight in prevalent cases increased from 83.4 to 92.1 kg for males and from 73.5 to 79.9 kg for females between 1995 and 2010 (p < 0.0001). For incident cases, the respective figures were 86.7 to 93.6 kg for males and 76.0 to 80.7 kg for females (p < 0.001). Between baseline and 6, 12 and 24 months, there were significant changes in weight for the majority of the treatment regimens selected for analysis. The largest weight increase at 12 months was for the patients who were prescribed a combination therapy with insulin and a thiazolidinedione, with a median increase of 4.1 kg (95% CI -0.60 to 8.0, p < 0.001). The largest weight decrease at 12 months was for the patients who were prescribed a combination therapy of metformin and exenatide, with a median decrease of -7.0 kg (95% CI -12.0 to -2.0, p < 0.001). Conclusions: There was a continual increase in body weight in people with T2DM over time, and considerable differences in the impact on weight using alternative treatment regimens. At the same time, glycaemic control remained relatively unchanged.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available